Related Experiment Video
Updated: May 18, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Metabolic Dysfunction-Associated Steatohepatitis: From Fibrosis-Based Risk Stratification to Emerging Therapeutic
1The Global NASH/MASH Council (GNC), Center for Outcomes Research in Liver Diseases, Washington, DC, USA; The Global Center for Liver Outcomes & Policy Research, Georgetown University School of Medicine, Washington, DC, USA.
No abstract available in PubMed .
Related Concept Videos
Cirrhosis II: Pathophysiology
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Cirrhosis I: Introduction
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

